Brain Cancer

This analysis demonstrated that the prognostic effect of age was predominately attributable to its association with molecular risk factors.

The primary end point of PFS-6 was met in the phase 2 NEO100-01 trial assessing NEO100 in patients with grade III/IV IDH1-mutant glioma.

Learn how to evaluate the data for recent advancements in immunotherapy, targeted therapy, and other modalities in the treatment of patients with glioma.

TRIDENT failed to show an OS benefit for TTFields started during chemoradiation vs the maintenance-phase approach in newly diagnosed glioblastoma.

Updated NCCN guidelines for CNS cancers now recommend CSF-based tumor-derived DNA testing for patients with biopsy-infeasible high-grade glioma or glioblastoma.

Early interim data from the 3 patients with recurrent glioblastoma showed 100% local disease control and a 67% complete response rate with Alpha DaRT.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

A personalized neoantigen vaccine plus an anti-PD-1 was feasible, safe, and generated durable anti-tumor immune responses in newly diagnosed glioblastoma.

Sonikpreet Aulakh, MBBS, MD, discussed the shift toward multiomic personalization and tumor microenvironment reprogramming in neuro-oncology.

The INCIPIENT trial establishes CARv3-TEAM-E as a mechanistically sophisticated and biologically active platform for recurrent glioblastoma.

The ASPHO Conference brings together the world’s leading experts in pediatric oncology and hematology, and this collection of posters detail new findings in care.

The conditional marketing authorization for tovorafenib in pediatric patients with low-grade glioma harboring a BRAF alteration is based on data from the FIREFLY-1 trial.

The FDA has granted FTD and cleared an IND application for daretabart, an anti-GD2 monoclonal antibody, for the treatment of high-risk neuroblastoma.

The FDA has set a Prescription Drug User Fee Act date of September 11, 2026, for TLX101-Px for patients with brain cancer.

Treatment with Rhenium-186 Obisbemeda for pediatric malignant gliomas and ependymomas is being assessed in the ReSPECT-PBC trial.

Results from a phase 1/2a trial and the ongoing FORTE basket study support the FDA’s regulatory decision for these patients with recurrent or progressive glioma.

The FDA has cleared an investigator-initiated investigational new drug application for a first-in-class AAV immuno-gene therapy in recurrent high-grade glioma.

FG001 is an investigational uPAR-targeting fluorophore designed to provide real-time illumination of aggressive brain tumors during surgical resection.

The irinotecan-based ChemoSeed delivery mechanism is currently under investigation for patients with malignant glioma in a registrational phase 2 trial.

The updated NDA submitted to the FDA included additional data and statistical analyses from existing clinical trials for pediatric and adult patients with glioma.

SRN-101, an AAV-based immuno-gene therapy, has received fast track designation for the treatment of recurrent high-grade glioma.

The FDA has cleared an IND application for FG001, allowing the developer to initiate its first US registration trial in patients with high-grade glioma.

Charlotte Ivey Rivers, MD, discussed the importance of rare CNS tumor research, upcoming trial data in meningioma, and the role of functional radiosurgery.

Findings from a phase 2 study demonstrate the feasibility of conducting genomically driven trials among patients with meningiomas.

The developer now plans to initiate a first-in-human clinical trial among patients with recurrent high-grade glioma.